Neurocrine Biosciences, Inc. (NASDAQ:NBIX) – Investment analysts at Leerink Swann increased their FY2017 earnings estimates for Neurocrine Biosciences in a research note issued to investors on Sunday, Zacks Investment Research reports. Leerink Swann analyst P. Matteis now expects that the company will post earnings of ($1.47) per share for the year, up from their prior forecast of ($1.67). Leerink Swann has a “Outperform” rating and a $83.00 price objective on the stock. Leerink Swann also issued estimates for Neurocrine Biosciences’ Q4 2017 earnings at $0.22 EPS, Q1 2018 earnings at ($0.07) EPS, Q2 2018 earnings at $0.03 EPS, Q3 2018 earnings at $0.31 EPS, Q4 2018 earnings at $0.18 EPS, FY2018 earnings at $0.46 EPS and FY2019 earnings at $2.04 EPS.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.36. The company had revenue of $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same period last year, the firm posted ($0.43) earnings per share.
Several other equities research analysts also recently commented on the company. BMO Capital Markets boosted their target price on Neurocrine Biosciences from $83.00 to $109.00 and gave the stock an “outperform” rating in a report on Thursday, November 2nd. Jefferies Group restated a “buy” rating and issued a $69.00 price target (up previously from $66.00) on shares of Neurocrine Biosciences in a research note on Tuesday, October 3rd. Oppenheimer set a $85.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Needham & Company LLC restated a “buy” rating and issued a $86.00 price target on shares of Neurocrine Biosciences in a research note on Thursday, November 2nd. Finally, Barclays boosted their price target on Neurocrine Biosciences from $75.00 to $85.00 and gave the stock an “overweight” rating in a research note on Thursday, November 2nd. One investment analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Neurocrine Biosciences presently has an average rating of “Buy” and a consensus target price of $82.31.
Shares of Neurocrine Biosciences (NASDAQ NBIX) opened at $75.88 on Wednesday. The company has a quick ratio of 14.37, a current ratio of 14.38 and a debt-to-equity ratio of 1.05. Neurocrine Biosciences has a 1-year low of $38.43 and a 1-year high of $83.84. The company has a market capitalization of $6,733.44, a price-to-earnings ratio of -34.18 and a beta of 0.35.
Large investors have recently added to or reduced their stakes in the business. First Trust Advisors LP grew its holdings in Neurocrine Biosciences by 29.0% during the third quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock valued at $47,963,000 after purchasing an additional 176,136 shares during the period. Janus Henderson Group PLC grew its holdings in Neurocrine Biosciences by 2.6% during the third quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock valued at $337,516,000 after purchasing an additional 140,639 shares during the period. Davidson Kempner Capital Management LP bought a new stake in Neurocrine Biosciences during the second quarter valued at about $3,639,000. Artisan Partners Limited Partnership bought a new stake in Neurocrine Biosciences during the second quarter valued at about $15,981,000. Finally, State Street Corp grew its holdings in Neurocrine Biosciences by 5.1% during the second quarter. State Street Corp now owns 2,710,196 shares of the company’s stock valued at $124,666,000 after purchasing an additional 131,141 shares during the period.
In other Neurocrine Biosciences news, insider Darin Lippoldt sold 1,979 shares of the business’s stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $79.36, for a total transaction of $157,053.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Dimitri E. Grigoriadis sold 30,000 shares of the business’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $74.58, for a total value of $2,237,400.00. Following the sale, the insider now directly owns 77,691 shares of the company’s stock, valued at approximately $5,794,194.78. The disclosure for this sale can be found here. In the last quarter, insiders have sold 116,405 shares of company stock valued at $8,588,519. 4.80% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: “Neurocrine Biosciences, Inc. to Post FY2017 Earnings of ($1.47) Per Share, Leerink Swann Forecasts (NBIX)” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/01/18/leerink-swann-brokers-lift-earnings-estimates-for-neurocrine-biosciences-inc-nbix.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Get a free copy of the Zacks research report on Neurocrine Biosciences (NBIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.